
    
      This is a Phase III, multicenter, double-masked, randomized, placebo-controlled,
      parallel-group study designed to evaluate the efficacy and safety of KPI-121 1.0% ophthalmic
      suspension versus placebo in subjects who require treatment of postoperative anterior ocular
      inflammation.
    
  